Bristol Myers bags a long-awaited FDA OK for ozanimod — but the pandemic will keep it off the market
The FDA has come through with the long-awaited approval of ozanimod, the once top MS drug hopeful that was sidelined by the agency 2 years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
